Once-Daily (od) Fluticasone Furoate/vilanterol (ff/vi: 100/25mcg) Compared With Twice-Daily (bd) Fluticasone Propionate/salmeterol (fsc: 250/50mcg) In Patients With COPD

被引：0
|
作者：
Dransfield, M. T. [1 ]
Crim, C. C. [2 ]
Feldman, G. [3 ]
Korenblat, P. E. [4 ]
Laforce, C. [5 ]
Locantore, N. [2 ]
Pistolesi, M. [6 ]
Watkins, M. [2 ]
Martinez, F. J. [7 ]
机构：
[1] Univ Alabama Birmingham, Birmingham, AL USA
[2] GlaxoSmithKline, Reseach Triangle Pk, NC USA
[3] South Carolina Pharmaceut Res, Spartanburg, SC USA
[4] Clin Res Ctr LLC, St Louis, MO USA
[5] Carolina Allergy & Asthma, Cary, NC USA
[6] Univ Florence, Florence, Italy
[7] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2013年 / 187卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A2432
引用
收藏
页数：1
相关论文
共 50 条
  • [31] The occurrence of pneumonia in COPD patients treated with salmeterol xinafoate 50mcg/fluticasone propionate 250mcg (SFC250) - Interim report of post-marketing surveillance in Japan
    Morioka, Yoriko
    Hara, Terufumi
    Kikkawa, Hideo
    Hitosugi, Hideki
    Yoshida, Pascal
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [32] Once-daily QVA149 significantly improves lung function and symptoms compared to twice-daily fluticasone/salmeterol in COPD patients: The ILLUMINATE study
    Vogelmeier, Claus
    Bateman, Eric
    Pallante, John
    Bryant, Hannah
    Alagappan, Vijay
    D'Andrea, Peter
    He, Ellie
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [33] Once-Daily Qva149 Demonstrates Superior Lung Function Compared To Twice-Daily Salmeterol/fluticasone In All Subgroups Of COPD Patients: The Illuminate Study
    Bateman, E. D.
    Vogelmeier, C.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [34] Once-Daily Qva149 Improves Breathlessness And Reduces Rescue Medication Use Compared To Twice-Daily Salmeterol/fluticasone In Patients With COPD: The Illuminate Study
    Bateman, E. D.
    Vogelmeier, C.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    Chen, H.
    Banerji, D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2013, 187
  • [35] 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
    David A. Lipson
    Ruby Birk
    Noushin Brealey
    Chang-Qing Zhu
    Advances in Therapy, 2020, 37 : 4894 - 4909
  • [36] 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study
    Lipson, David A.
    Birk, Ruby
    Brealey, Noushin
    Zhu, Chang-Qing
    ADVANCES IN THERAPY, 2020, 37 (12) : 4894 - 4909
  • [37] Impact Of Initiating Fluticasone Propionate-Salmeterol Combination 250/50mcg (FSC) Following A Hospitalization Or Emergency Department Visit Related To Chronic Obstructive Pulmonary Disease (COPD)
    Dalal, A. A.
    Shah, M.
    D'Souza, A. O.
    Dhamane, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [38] Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily
    Busse, W
    Koenig, SM
    Oppenheimer, J
    Sahn, SA
    Yancey, SW
    Reilly, D
    Edwards, LD
    Dorinsky, PM
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (01) : 57 - 65
  • [39] ONCE-DAILY QVA149 PROVIDES SUPERIOR BRONCHODILATION AND IMPROVES LUNG FUNCTION VERSUS TWICE-DAILY FLUTICASONE/SALMETEROL IN COPD PATIENTS: THE ILLUMINATE STUDY
    Vogelmeier, C.
    Bateman, E.
    Pallante, J.
    Bryant, H.
    Alagappan, V.
    D'Andrea, P.
    He, E.
    Banerji, D.
    THORAX, 2012, 67 : A149 - A149
  • [40] Once-daily indacaterol/glycopyrronium (IND/GLY) reduces all exacerbations compared with twice-daily salmeterol/fluticasone (SFC) in COPD patients with ≥ 1 exacerbation in the previous year: The FLAME study
    Wedzicha, Jadwiga
    Vogelmeier, Claus F.
    Ayers, Tim
    FowlerTaylor, Angel
    Thach, Chau
    Olsson, Petter
    Fogel, Robert
    Patalano, Francesco
    Banerji, Donald
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345